NB4168, a patented therapeutic candidate designed to have significantly increased bioavailability and a differentiated safety and pharmacokinetic profile compared to NRC, is the first investigational product to advance the Company's NAD+ platform into regulated drug development

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ science, today announced the formal launch of the first drug candidate of NAD Pharmaceuticals Corp., its wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases. The program will primarily focus on how NAD+, a coenzyme central to energy metabolism, DNA repair, mitochondrial function and cellular stress responses, modulates in rare diseases for which DNA misrepair and mitochondrial dysfunction are foundational underlying causes. This represents a strategic expansion of Niagen Bioscience's NAD+ platform from cellular-health innovation into regulated drug development. A derivative of the NAD+ precursor, nicotinamide riboside (NR), NB4168 is the first publicly announced investigational pharmaceutical product candidate within the program, with Ataxia Telangiectasia (A-T) as the initial indication.